As part of our semaglutide program, JY MedTech has successfully completed the registration of the semaglutide active pharmaceutical ingredient (API) Korean Drug Master File (K-DMF) in South Korea. The API registration certificate has been issued by the Korean Ministry...
JYMed Peptide has been independently assessed by EcoVadis Bronze Medal Dec 2025, a globally recognized sustainability ratings provider used across supply chains. In the December 2025 assessment, JYMed Peptide achieved an overall score of 70/100, placing us in the 83rd...
中文
